Expert opinion on biological therapy
-
Expert Opin Biol Ther · Aug 2021
An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma.
Introduction: B-cell maturation antigen (BCMA) targeted therapy (BCMA-TT) has emerged as a promising treatment for Multiple Myeloma (MM). the three most common treatment modalities for targeting BCMA are antibody-drug conjugates (ADCs), bispecific antibody constructs, including BiTE (bispecific T-cell engager) immuno-oncology therapies, and chimeric antigen receptor (CAR)-modified T-cell therapy. Areas covered: The review provides an overview of the main published studies on clinical and pre-clinical data from trials using BCMA-TT. Expert opinion: Despite progresses in survival outcomes and the availability of new drugs, MM remains an incurable disease. ⋯ CAR-T cells produced unprecedented results in heavily pretreated RRMM. The most common toxicities include neurologic toxicity and cytokine release syndrome, B-cell aplasia, cytopenias, and hypogammaglobulinemia. Further studies are needed to detect which are the eligible patients who could benefit from one treatment more than another.